NCT05667077

The Effect of Amantadine on Post-COVD-19 Fatigue

The Effect of Amantadine on Post-COVD-19 Fatigue: a Clinical Trial

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 83 (estimated)
• Sponsor: Shahid Beheshti University of Medical Sciences · Academic / Other
• Sex: All
• Age: 20 Years – 50 Years
• Healthy volunteers: Not accepted

Summary

This study aimed to investigate amantadine's safety and its effect on reducing post-COVID-19 fatigue.

Detailed description

Background The 2019 coronavirus disease has severely affected the health of the general public. Even after recovery, this disease can cause problems, including chronic fatigue, which the patient can suffer from for years and cause permanent disability for a number of patients. Despite the fact that fatigue due to COVID-19 has affected many patients, not many studies have been done in the field of effective treatment for this problem. In this study, the investigators studied the effect of amantadine on the fatigue of COVID-19 patients. Method In this clinical trial study, 83 patients were randomly included in the study from the patients referred to the internal clinic of Shohada Tajrish Hospital in Tehran, and they were initially evaluated by VAFS and FSS questionnaires. 17 patients were initially excluded due to having at least one exclusion criterion. And 66 patients were randomly divided between two groups using amantadine and the control group. The amantadine group was treated with amantadine capsules 100 mg BD for 2 weeks and after 2 weeks again for both The group questionnaire was completed, and the data was analyzed by SPSS software version 26.

Conditions

• Post-COVID-19 Syndrome

Interventions

Type	Name	Description
DRUG	Amantadine	The amantadine group is treated with amantadine capsules 100mg twice a day for two weeks

Timeline

• Start date: 2022-12-26
• Primary completion: 2022-12-29
• Completion: 2023-01-10
• First posted: 2022-12-28
• Last updated: 2022-12-28

Locations

1 site across 1 country: Iran